1887

Abstract

A nested case–control study of invasive and cervical cancer was performed within a community-based cohort of 13 595 Taiwanese women assembled in 1991, with a follow-up period of 9 years. Baseline serum or plasma samples were analysed for antibodies against human papillomavirus (HPV) types 6, 16 and 18 and . In total, 114 cases (42 incident cases identified during follow-up and 72 prevalent cases identified at baseline) and 519 matched controls were included in the study. HPV-16 seropositivity was strongly associated with cervical cancer (OR=6.33; 95 % CI 3.45–11.62). Overall, was not associated with cervical cancer, but was associated with cervical cancer in analyses restricted to incident cases of cancer (OR=2.94; 95 % CI 1.17–7.42) or to cases in which serum samples were analysed (OR=3.13; 95 % CI 1.16–8.47). An antagonistic interaction between HPV-6 and -16 was found in a multiplicative model. These results suggest that different HPV types might interfere in cervical carcinogenesis and that is associated with cervical cancer in prospective studies, and support the notion that HPV-16 seropositivity is strongly associated with cervical cancer.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.82503-0
2007-03-01
2019-11-19
Loading full text...

Full text loading...

/deliver/fulltext/jgv/88/3/814.html?itemId=/content/journal/jgv/10.1099/vir.0.82503-0&mimeType=html&fmt=ahah

References

  1. af Geijersstam, V., Kibur, M., Wang, Z., Koskela, P., Pukkala, E., Schiller, J., Lehtinen, M. & Dillner, J. ( 1998; ). Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis 177, 1710–1714.[CrossRef]
    [Google Scholar]
  2. Andersson-Ellström, A., Dillner, J., Hagmar, B., Schiller, J. T., Sapp, M., Forssman, L. & Milsom, I. ( 1996; ). Comparison of development of serum antibodies to HPV16 and HPV33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls. A longitudinal cohort study. Sex Transm Dis 23, 234–238.[CrossRef]
    [Google Scholar]
  3. Anttila, T., Saikku, P., Koskela, P., Bloigu, A., Dillner, J., Ikaheimo, I., Jellum, E., Lehtinen, M. & Lenner, P. ( 2001; ). Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA 285, 47–51.[CrossRef]
    [Google Scholar]
  4. Bosch, F. X., Manos, M. M., Muñoz, N., Sherman, M., Jansen, A. M., Peto, J., Schiffman, M. H., Moreno, V., Kurman, R. & Shah, K. V. ( 1995; ). Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 87, 796–802.[CrossRef]
    [Google Scholar]
  5. Clifford, G. M., Smith, J., Aguado, T. & Franceschi, S. ( 2003; ). Comparison of HPV type distribution in highgrade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 89, 101–105.[CrossRef]
    [Google Scholar]
  6. Combita, A.-L., Bravo, M.-M., Touzé, A., Orozco, O. & Coursaget, P. ( 2002; ). Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in Colombian women with invasive cervical cancer. Int J Cancer 97, 796–803.[CrossRef]
    [Google Scholar]
  7. Dillner, J., Wiklund, F., Lenner, P., Eklund, C., Fredriksson-Shanazarian, V., Schiller, J. T., Hibma, M., Hallmans, G. & Stendahl, U. ( 1995; ). Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer. Int J Cancer 60, 377–382.
    [Google Scholar]
  8. Dillner, J., Kallings, I., Brihmer, C., Sikström, B., Koskela, P., Lehtinen, M., Schiller, J. T., Sapp, M. & Mårdh, P. ( 1996; ). Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. J Infect Dis 173, 1394–1398.[CrossRef]
    [Google Scholar]
  9. Dillner, J., Lehtinen, M., Björge, T., Luostarinen, T., Youngman, L., Jellum, E., Koskela, P., Gislefoss, R. E. & Hallmans, G. ( 1997; ). Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. J Natl Cancer Inst 89, 1293–1299.[CrossRef]
    [Google Scholar]
  10. Evander, M., Edlund, K., Gustafsson, A., Jonsson, M., Karlsson, R., Rylander, E. & Wadell, G. ( 1995; ). Human papillomavirus infection is transient in young women: a population-based cohort study. J Infect Dis 171, 1026–1030.[CrossRef]
    [Google Scholar]
  11. Grabowska, K., Wang, X., Jacobsson, A. & Dillner, J. ( 2002; ). Evaluation of cost-precision ratios of different strategies for ELISA measurement of serum antibody levels. J Immunol Methods 271, 1–15.[CrossRef]
    [Google Scholar]
  12. Herrero, R., Hildesheim, A., Bratti, C., Sherman, M. E., Hutchinson, M., Morales, J., Balmaceda, I., Greenberg, M. D. & Alfaro, M. ( 2000; ). Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 92, 464–474.[CrossRef]
    [Google Scholar]
  13. Hildesheim, A., Schiffman, M., Gravitt, P., Glass, A. G., Greer, C. E., Zhang, T., Scott, D. R., Rush, B. B. & Lawler, P. ( 1994; ). Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 169, 235–240.[CrossRef]
    [Google Scholar]
  14. Ho, G. Y., Bierman, R., Beardsley, L., Chang, C. & Burk, R. ( 1998; ). Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338, 423–428.[CrossRef]
    [Google Scholar]
  15. Hosmer, D. W. & Lemeshow, S. ( 1992; ). Confidence interval estimation of interaction. Epidemiology 3, 452–456.[CrossRef]
    [Google Scholar]
  16. Kirnbauer, R., Taub, J., Greenstone, H., Roden, R., Durst, M., Gissman, L., Lowy, D. R. & Schiller, J. T. ( 1993; ). Efficient self-assembly of human papillomavirus type 16 L1 and L1–L2 into virus-like particles. J Virol 67, 6929–6936.
    [Google Scholar]
  17. Kjellberg, L., Wang, Z., Wiklund, F., Edlund, K., Angstrom, T., Lenner, P., Sjoberg, I., Hallmans, G. & Wallin, K. L. ( 1999; ). Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case–control study. J Gen Virol 80, 391–398.
    [Google Scholar]
  18. Koskela, P., Anttila, T., Bjorge, T., Brunsvig, A., Dillner, J., Hakama, M., Hakulinen, T., Jellum, E. & Lehtinen, M. ( 2000; ). Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer 85, 35–39.[CrossRef]
    [Google Scholar]
  19. Lehtinen, M., Dillner, J., Knekt, P., Luostarinen, T., Aromaa, A., Kirnbauer, R., Koskela, P., Paavonen, J. & Peto, R. ( 1996; ). Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case–control study. BMJ 312, 537–539.[CrossRef]
    [Google Scholar]
  20. Liaw, K. L., Hsing, A. W., Chen, C. J., Schiffman, M. H., Zhang, T. Y., Hsieh, C. Y., Greer, C. E., You, S. L. & Huang, T. W. ( 1995; ). Human papillomavirus and cervical neoplasia: a case–control study in Taiwan. Int J Cancer 62, 565–571.[CrossRef]
    [Google Scholar]
  21. Luostarinen, T., Af Geijersstam, V., Björge, T., Eklund, C., Hakama, M., Hakulinen, T., Jellum, E., Koskela, P. & Paavonen, J. ( 1999; ). No excess risk of cervical carcinoma among women seropositive for both HPV16 and HPV6/11. Int J Cancer 80, 818–822.[CrossRef]
    [Google Scholar]
  22. Luostarinen, T., Lehtinen, M., Björge, T., Abeler, V., Hakama, M., Hallmans, G., Jellum, E., Koskela, P. & Lenner, P. ( 2004; ). Joint effects of different human papillomaviruses and Chlamydia trachomatis infections on risk of squamous cell carcinoma of the cervix uteri. Eur J Cancer 40, 1058–1065.[CrossRef]
    [Google Scholar]
  23. Matsumoto, K., Yoshikawa, H., Yasugi, T., Nakagawa, S., Kawana, K., Takeoka, A., Yaegashi, N., Iwasaka, T. & Kanazawa, K. ( 2003; ). IgG antibodies to human papillomavirus 16, 52, 58 and 6 L1 capsids: case-control study of cervical intraepithelial neoplasia in Japan. J Med Virol 69, 441–446.[CrossRef]
    [Google Scholar]
  24. Muñoz, N., Bosch, F. X., de Sanjosé, S., Herrero, R., Castellsagué, X., Shah, K. V., Snijders, P. J. & Meijer, C. J. ( 2003; ). Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348, 518–527.[CrossRef]
    [Google Scholar]
  25. Nauclér, P., da Costa, F. M., Ljungberg, O., Bugalho, A. & Dillner, J. ( 2004; ). Human papillomavirus genotyped in cervical cancers in Mozambique. J Gen Virol 85, 2189–2190.[CrossRef]
    [Google Scholar]
  26. Olsen, A. O. O., Dillner, J., Gjöen, K. & Magnus, P. ( 1997; ). Seropositivity against HPV16 capsids: a better marker of past sexual behaviour than presence of HPV DNA. Genitourin Med 73, 131–135.
    [Google Scholar]
  27. Paavonen, J. & Eggert-Kruse, W. ( 1999; ). Chlamydia trachomatis: impact on human reproduction. Hum Reprod Update 5, 433–447.[CrossRef]
    [Google Scholar]
  28. Parkin, D. M., Pisani, P. & Ferlay, J. ( 1993; ). Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 54, 594–606.[CrossRef]
    [Google Scholar]
  29. Puolakkainen, M., Vesterinen, E., Purola, E., Saikku, P. & Paavonen, J. ( 1986; ). Persistence of chlamydial antibodies after pelvic inflammatory disease. J Clin Microbiol 23, 924–928.
    [Google Scholar]
  30. Rothman, K. J. & Greenland, S. ( 1998; ). Concepts of interaction. In Modern Epidemiology, 2nd edn, pp. 329–342. Edited by K. J. Rothman & S. Greenland. Philadelphia, PA: Lippincott–Raven.
  31. Schiffman, M. H. ( 1992; ). Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst 84, 394–398.[CrossRef]
    [Google Scholar]
  32. Shah, K. V., Viscidi, R. P., Alberg, A. J., Helzlsouer, K. J. & Comstock, G. W. ( 1997; ). Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix. Cancer Epidemiol Biomarkers Prev 6, 233–237.
    [Google Scholar]
  33. Sigurgeirsson, B., Lindelöf, B. & Eklund, G. ( 1991; ). Condylomata acuminata and risk of cancer: an epidemiological study. BMJ 303, 341–344.[CrossRef]
    [Google Scholar]
  34. Silins, I., Wang, Z., Avall-Lundqvist, E., Frankendal, B., Vikmanis, U., Sapp, M., Schiller, J. T. & Dillner, J. ( 1999; ). Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis. J Gen Virol 80, 2931–2936.
    [Google Scholar]
  35. Silins, I., Tedeschi, R. M., Kallings, I. & Dillner, J. ( 2002; ). Clustering of seropositivities for sexually transmitted infections. Sex Transm Dis 29, 207–211.[CrossRef]
    [Google Scholar]
  36. Silins, I., Wang, X., Tadesse, A., Jansen, K. U., Schiller, J. T., Åvall-Lundqvist, E., Frankendahl, B. & Dillner, J. ( 2004; ). A population-based study of cervcal carcinoma and HPV infection in Latvia. Gynecol Oncol 93, 484–492.[CrossRef]
    [Google Scholar]
  37. Silins, I., Ryd, W., Strand, A., Wadell, G., Törnberg, S., Hansson, B. G., Wang, X., Arnheim, L. & Dahl, V. ( 2005; ). Chlamydia trachomatis infection and persistence of human papillomavirus. Int J Cancer 116, 110–115.[CrossRef]
    [Google Scholar]
  38. Smith, J. S., Bosetti, C., Muñoz, N., Herrero, R., Bosch, F. X., Eluf-Neto, J., Meijer, C. J., Van Den Brule, A. J. & Franceschi, S. ( 2004; ). Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case–control study. Int J Cancer 111, 431–439.[CrossRef]
    [Google Scholar]
  39. Sun, C. A., Liu, J., Wu, D., Nieh, S., Yu, C. & Chu, T. ( 2002; ). Viral load of high-risk human papillomavirus in cervical squamous intraepithelial lesions. Int J Gynaecol Obstet 76, 41–47.[CrossRef]
    [Google Scholar]
  40. Walboomers, J. M., Jacobs, M. V., Manos, M. M., Bosch, F. X., Kummer, J. A., Shah, K. V., Snijders, P. J., Peto, J., Meijer, C. J. & Muñoz, N. ( 1999; ). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189, 12–19.[CrossRef]
    [Google Scholar]
  41. Wang, P. D. & Lin, R. S. ( 1996; ). a Epidemiology of cervical cancer in Taiwan. Gynecol Oncol 62, 344–352.[CrossRef]
    [Google Scholar]
  42. Wang, P. D. & Lin, R. S. ( 1996; ). b Risk factors for cervical intraepithelial neoplasia in Taiwan. Gynecol Oncol 62, 10–18.[CrossRef]
    [Google Scholar]
  43. Wang, S. P. & Grayston, J. T. ( 1970; ). Immunologic relationship between genital TRIC, lymphogranuloma venereum, and related organisms in a new microtiter indirect immunofluorescence test. Am J Ophthalmol 70, 367–374.[CrossRef]
    [Google Scholar]
  44. Wang, Z., Konya, J., Åvall-Lundkvist, E., Sapp, M., Dillner, J. & Dillner, L. ( 1997; ). Human papillomavirus antibody responses among patients with incident cervical carcinoma. J Med Virol 52, 436–440.[CrossRef]
    [Google Scholar]
  45. Woodward, M. ( 1999; ). Epidemiology: Study Design and Data Analysis. Boca Raton, FL: Chapman & Hall/CRC.
  46. Zenilman, J. M. ( 2001; ). Chlamydia and cervical cancer: a real association?. JAMA 285, 81–83.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.82503-0
Loading
/content/journal/jgv/10.1099/vir.0.82503-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error